Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | CTSG | P08311 | 1/20 | 0.33 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.33 |
| ▸ | CMA1 | P23946 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4346271 | 0.77 | CYP2C19 (0.36) | CYP2D6CYP2C19PRSS1CTSGCTRB1 | |
| SCHEMBL16480859 | 0.77 | CYP2D6 (0.39) | CYP2D6CYP2C19PRSS1CTSGCTRB1 | |
| SCHEMBL13743905 | 0.76 | TDP1 (0.43) | CYP2D6 | |
| SCHEMBL31112120 | 0.74 | CYP2C19 (0.33) | CYP2D6CYP2C19PRSS1CTSGCTRB1 | |
| SCHEMBL12667948 | 0.74 | CTSD (0.35) | — | |
| SCHEMBL4241152 | 0.72 | — | — | |
| SCHEMBL2153338 | 0.72 | — | — | |
| SCHEMBL2040611 | 0.72 | — | — | |
| SCHEMBL1934610 | 0.71 | — | — | |
| Hydrochloric Acid SCHEMBL25356401 | 0.70 | CYP2D6 (0.37) | CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215743-A1 | Tricyclic benzazepine derivatives and their use | BAYER HEALTHCARE AG (DE) | 2009-08-27 | — | — | US | disclosed |
| CN-1926143-A | Tricyclic benzazepine * derivatives as squalene synthase inhibitors for the treatment of cardiovascular diseases | BAYER HEALTHCARE AG (DE) | 2007-03-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215743-A1 | Tricyclic benzazepine derivatives and their use | CACNA1I, HDAC3, AADAC | CYP2D6 597/4885CYP2C19 284/4885PRSS1 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.